Eisai Co.’s much-anticipated findings on its experimental Alzheimer’s drug provided tinder for a debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.
Lecanemab, developed with help from Biogen Inc., cleared plaque that clogs patients’ brains and slowed their mental decline by 27% over 18 months. Yet the improvements came at the price of side effects like brain swelling and bleeding in more than one in five people on the medicine, compared to 10% of those who received a placebo.
Eisai offices in Nutley, New Jersey.
Source: PR Newswire
The findings presented at the Clinical Trials on Alzheimer’s Disease conference ...
